Evidence map›Paper›PMID 34693864›Full record

ArticleGut microbes

Fungal lysozyme leverages the gut microbiota to curb DSS-induced colitis.

Ida Søgaard Larsen, Benjamin A H Jensen, Erica Bonazzi, Béatrice S Y Choi, Nanna Ny Kristensen, Esben Gjerløff Wedebye Schmidt, Annika Süenderhauf, Laurence Morin, Peter Bjarke Olsen, Lea Benedicte Skov Hansen and 4 more

Open access · goldAbstract read
In one paragraph

Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Frontiers in microbiology · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Pharmacokinetic Profiling UsingInternational journal of molecular sciences · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 5 countries.

Ida Søgaard LarsenQuebec Heart and Lung Institute (Iucpq), Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Québec, Canada.
Benjamin A H JensenQuebec Heart and Lung Institute (Iucpq), Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Québec, Canada.ORCID 0000-0001-6991-0828
Erica BonazziInserm U1016, Team "Mucosal Microbiota in Chronic Inflammatory Diseases", Université De Paris, Paris, France.
Béatrice S Y ChoiQuebec Heart and Lung Institute (Iucpq), Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Québec, Canada.
Nanna Ny KristensenNovozymes A/S, Bagsværd, Denmark.
Esben Gjerløff Wedebye SchmidtNovozymes A/S, Bagsværd, Denmark.
Annika SüenderhaufInstitute of Nutritional Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
Laurence MorinQuebec Heart and Lung Institute (Iucpq), Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Québec, Canada.
Peter Bjarke OlsenNovozymes A/S, Bagsværd, Denmark.
Lea Benedicte Skov HansenNovozymes A/S, Bagsværd, Denmark.
Torsten SchröderInstitute of Nutritional Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
Christian SinaInstitute of Nutritional Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
Benoît ChassaingInserm U1016, Team "Mucosal Microbiota in Chronic Inflammatory Diseases", Université De Paris, Paris, France.
André MaretteQuebec Heart and Lung Institute (Iucpq), Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Québec, Canada.
Novozymes (Denmark) · DKUniversité Laval · CAUniversity Hospital Schleswig-Holstein · DEInserm · FRUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colitis is characterized by colonic inflammation and impaired gut health. Both features aggravate obesity and insulin resistance. Host defense peptides (HDPs) are key regulators of gut homeostasis and generally malfunctioning in above-mentioned conditions. We aimed here to improve bowel function in diet-induced obesity and chemically induced colitis through daily oral administration of lysozyme, a well-characterized HDP, derived from

Indexed as

AcremoniumAnimalsBacteriaColitisDextran SulfateDisease Models, AnimalFemaleGastrointestinal MicrobiomeHumansMaleMiceMice, Inbred BALB CMice, Inbred C57BLMuramidaseDextran SulfateMuramidasecolitisGut healthhigh fat diethost defense peptidesinsulin resistanceintestinal inflammationmicrobiota encroachmentmicrobiota functionmucusmuramidase

Identifiers

PMID34693864
PMCPMC8547870
OpenAlexW3210049562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.